NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./

VANCOUVER, BC, March 21, 2024 /CNW/ - NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV: NGEN) is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Stifel Canada, Canaccord Genuity and PI Financial (collectively, the "Underwriters"), who have agreed to purchase, on a "bought deal" basis 8,515,000 units (the "Units") of the Company at a price of $2.35 per Unit, for aggregate gross proceeds of $20,010,250 (the "Offering").